For patients living with neovascular age-related macular degeneration (nAMD), the sudden appearance of blood beneath the retina can be a terrifying turning point. This condition, known as subretinal hemorrhage (SRH), acts as a physical barrier between the photoreceptors and the underlying support system of the eye, often leading to rapid vision loss if not addressed with precision. As a physician and health journalist, I have seen how the complexity of these cases often leaves patients and providers questioning the best path forward: is the condition manageable with medication, or is urgent surgery required?
The answer, according to emerging clinical perspectives, lies in the measurement. Recent insights presented by J. Fernando Arevalo, MD, PhD, at the Retina World Congress, suggest that subretinal hemorrhage treatment options are fundamentally dictated by the size and classification of the bleed. By utilizing a standardized measurement system based on the optic disc diameter, specialists can more accurately predict visual outcomes and determine whether a patient is a candidate for surgical intervention or should remain on a nonsurgical regimen.
This shift toward a size-based classification system is critical because subretinal blood is not a static entity; It’s toxic. When blood lingers in the subretinal space, it can cause permanent damage to the retinal pigment epithelium (RPE) and the photoreceptors. The goal of modern management is not just to remove the blood, but to do so within a window of time that preserves the possibility of functional vision. For the approximately 12% of patients with neovascular AMD who develop these hemorrhages, the difference between a “minor” and “large” classification can be the difference between maintaining independence and facing legal blindness.
The Measurement Standard: Understanding Disc Diameter (DD)
In the field of ophthalmology, the “disc diameter” (DD) serves as a vital internal ruler. Because every eye differs slightly in size, using a fixed millimeter measurement is less reliable than using the patient’s own optic nerve head—the optic disc—as a reference point. By calculating how many “discs” wide a hemorrhage is, surgeons can categorize the severity of the bleed regardless of the patient’s individual ocular anatomy.
According to the framework discussed by Dr. Arevalo, subretinal hemorrhages are categorized into three primary classifications based on size:
- Small: Hemorrhages measuring between 1 and less than 4 disc diameters.
- Medium: Hemorrhages that exceed the “small” threshold but do not yet encompass the entire macula.
- Large: Extensive hemorrhages that cover a significant portion of the central vision area.
This classification is not merely academic; it serves as a triage tool. Small hemorrhages may be managed conservatively, while medium and large hemorrhages often require more aggressive intervention to prevent the blood from consolidating into a hard clot that becomes impossible to remove without causing further trauma to the retina. For more information on how macular degeneration affects the retina, the National Eye Institute provides comprehensive resources on the disease’s progression.
Nonsurgical Management: The Role of Anti-VEGF Therapy
For patients with small subretinal hemorrhages, the primary line of defense is typically nonsurgical. The cornerstone of this approach is the administration of anti-vascular endothelial growth factor (anti-VEGF) agents. These medications are injected into the vitreous of the eye to inhibit the growth of the abnormal, leaky blood vessels that cause the hemorrhage in the first place.
Anti-VEGF therapy works by “drying up” the leaky vessels and reducing the edema (swelling) associated with the bleed. In many small-scale hemorrhages, the body can reabsorb the blood naturally over time, provided the underlying cause—the neovascularization—is controlled. However, the limitation of this approach is that anti-VEGF agents cannot “dissolve” a large, established clot of blood. When the volume of the hemorrhage is too great, the medication may treat the cause but cannot remove the physical obstruction blocking the patient’s sight.
The decision to stick with nonsurgical management depends heavily on the patient’s baseline vision and the stability of the hemorrhage. If the bleed is small and the patient’s vision remains relatively stable, the risks of surgery—such as retinal detachment or infection—often outweigh the potential benefits of mechanical blood removal.
Surgical Interventions for Medium and Large Hemorrhages
When a hemorrhage is classified as medium or large, the risk of permanent photoreceptor death increases significantly. In these cases, surgeons may opt for more invasive procedures to physically displace or dissolve the blood. One of the most discussed techniques is pneumatic displacement, where a gas bubble is injected into the eye to physically push the blood away from the fovea (the center of the macula), allowing the patient to regain some central vision.
Another advanced option involves the use of tissue plasminogen activator (t-PA). This represents a thrombolytic agent—essentially a “clot-buster”—that can be administered directly into the hematoma during a pars plana vitrectomy. By breaking down the fibrin mesh that holds the clot together, t-PA helps liquefy the blood, making it easier to evacuate from the subretinal space. This surgical approach is typically reserved for cases where the volume of blood is too great for natural reabsorption and the urgency of the visual threat justifies the risks of intraocular surgery.
The timing of these surgeries is paramount. Clinical data suggests that the volume of the clot and the time elapsed before evacuation are the strongest prognostic factors for visual recovery. The longer blood remains in the subretinal space, the more the surrounding tissue becomes toxic, reducing the likelihood that vision will return even if the blood is successfully removed. High-authority clinical reviews on PubMed emphasize that early intervention in large hemorrhages is key to preventing permanent macular scarring.
Comparing Treatment Pathways by Hemorrhage Size
To better understand how size dictates the clinical path, it is helpful to look at the general strategy applied to each classification. While every patient’s case is unique, the following framework represents the current clinical thinking in the management of nAMD-related bleeds:
| Hemorrhage Size | Primary Treatment Goal | Typical Intervention |
|---|---|---|
| Small (1 to <4 DD) | Control leakage; allow natural reabsorption. | Anti-VEGF injections. |
| Medium | Reduce volume; prevent central foveal damage. | Combination of anti-VEGF and potential pneumatic displacement. |
| Large | Rapid evacuation of blood to save photoreceptors. | Vitrectomy with t-PA or pneumatic displacement. |
What This Means for Patients and Caregivers
For those managing age-related macular degeneration, the most significant takeaway is the necessity of immediate action. A subretinal hemorrhage is a medical emergency in the context of vision. If you notice a sudden “dark spot” or a “curtain” falling over your central vision, you should contact a retinal specialist immediately. The window for surgical success is narrow, and the classification of the bleed—small, medium, or large—will be the primary driver of your treatment plan.
It is also important to manage expectations. While surgical evacuation can remove the blood, it cannot “fix” the underlying AMD or replace photoreceptors that have already died. However, by removing the toxic blood quickly, surgeons can prevent further loss and, in some cases, salvage a degree of vision that would otherwise be lost forever. The goal is to shift the outcome from “permanent blindness” to “managed vision loss.”
As we move toward more personalized medicine, the use of precise measurements like disc diameter allows doctors to move away from a “one size fits all” approach. By tailoring the intervention to the specific volume of the hemorrhage, the medical community is improving the prognosis for the 12% of nAMD patients who face this daunting complication.
The medical community continues to refine these protocols, with ongoing research into more effective thrombolytic agents and less invasive displacement techniques. Patients are encouraged to stay in close contact with their healthcare providers and follow a strict schedule of monitoring and anti-VEGF injections to reduce the risk of future hemorrhages.
The next major milestone for the field will be the continued release of longitudinal data from the Retina World Congress and similar forums, which will further validate these size-based classification systems across larger, more diverse patient populations.
Do you or a loved one manage AMD? Have you experienced the challenges of subretinal hemorrhage? We invite you to share your experiences in the comments below or share this article with others who may find this clinical guidance helpful.